Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, withdrew its plans for an initial public offering on Wednesday. It originally filed in August 2023 with a proposed deal size of $40 million.
The New Taipei City, Taiwan-based company was founded in 2002 and had planned to list on the Nasdaq under the symbol JYB. Joseph Stone Capital was set to be the sole bookrunner on the deal.
